http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Nae Yun Heo ),( Young Suk Lim ),( Woochang Lee ),( Minkyung Oh ),( Jiyun An ),( Dan Bi Lee ),( Ju Hyun Shim ),( Kang Mo Kim ),( Han Chu Lee ),( Yung Sang Lee ),( Dong Jin Suh2 ) 대한간학회 2014 Clinical and Molecular Hepatology(대한간학회지) Vol.20 No.2
Background/Aims: There are few available data regarding the association between the single nucleotide polymorphisms (SNPs) of the gene encoding interleukin 28B (IL28B) and a sustained virologic response (SVR) to peginterferon (PEG-IFN) plus ribavirin (RBV) therapy in Korean chronic hepatitis C patients. Methods: This was a retrospective cohort study of 156 patients with chronic hepatitis C virus (HCV) infection who received combination treatment of PEG-IFN plus RBV. Blood samples from these patients were analyzed to identify the IL28B SNPs at rs12979860, rs12980275, rs8099917, and rs8103142. Association analyses were performed to evaluate the relationships between each IL28B SNP and SVRs. Results: Seventy six patients with HCV genotype 1 and 80 with genotype non-1 were enrolled. The frequencies of rs12979860 CC and CT genotypes were 90.4% and 9.6%, respectively; those of rs12980275 AA and AG genotypes were 87.2% and 12.8%, respectively; those of rs8099917 TT and TG genotypes were 92.3% and 7.7%, respectively; and those of rs8103142 TT and CT genotypes were 90.4% and 9.6%, respectively. Among the patients with HCV genotype 1, the SVR rates were 69.7% and 80.0% for rs12979860 CC and CT, respectively (P=0.71). Among the HCV genotype non-1 patients, SVR rates were 88.0% and 100% for rs12979860 CC and CT (P=1.00), respectively. Conclusions: Genotypes of the IL28B SNP that are known to be favorable were present in most of the Korean patients with chronic hepatitis C in this study. Moreover, the IL28B SNP did not influence the SVR rate in either the HCV genotype 1 or non-1 patients. Therefore, IL28B SNP analysis might be not useful for the initial assessment, prediction of treatment outcomes, or treatment decision-making of Korean chronic hepatitis C patients. (Clin Mol Hepatol 2014;20:177-184)
( Nae Yun Heo ),( Young Suk Lim ),( Ji Hyun An ),( Sun Young Ko ),( Heung Bum Oh ) 대한간학회 2012 Clinical and Molecular Hepatology(대한간학회지) Vol.18 No.4
Background/Aims: The early diagnosis of acute hepatitis A (AHA) is hindered because serum IgM against hepatitis A virus (HAV) can yield false-negative results during the window period. This study evaluated the diagnostic accuracy of a polymerase chain reaction (PCR) kit for HAV RNA for the diagnosis of AHA. Methods: Samples were collected from 136 patients with acute severe hepatitis at their admission to Asan Medical Center between June 2010 and July 2010. Samples were analyzed for serum IgM anti-HAV using an immunoassay test and for qualitative HAV RNA using the Magicplex HepaTrio PCR test kit. The diagnostic accuracies of these methods were tested on the basis of clinical and laboratory diagnoses of AHA. Results: The concordance rate and kappa value between IgM anti-HAV and HAV RNA PCR were 88.2% and 0.707, respectively. For the diagnosis of AHA, the sensitivity and specificity of IgM anti-HAV were 90.7% and 100%, respectively, when an "equivocal" result was regarded as positive; and 79.1% and 100%, respectively, when an "equivocal" result was regarded as negative. The sensitivity and specificity of HAV RNA PCR were 81.4% and 100%, respectively. All four patients with negative IgM anti-HAV and positive HAV RNA PCR results and all four patients with equivocal IgM anti-HAV RNA and positive HAV RNA PCR results were eventually diagnosed with AHA. Conclusions: The qualitative HAV RNA PCR test has an equivalent diagnostic accuracy for AHA compared to IgM anti-HAV and may be more sensitive during the window period. (Clin Mol Hepatol 2012;18:397-403)
The Prevalence of Colonic Neoplasm in Cryptogenic Pyogenic Liver Abscess: A Prospectively Enrolled
( Nae-yun Heo ),( Tae Oh Kim ),( Young Soo Moon ),( Sung Yeun Yang ),( Seung Ha Park ),( Jong Ha Park ),( Joon Hyuk Choi ),( Sung-min Kim ),( Ki Tae Yoon ),( Young Mi Hong ),( Mong Cho ) 대한간학회 2016 춘·추계 학술대회 (KASL) Vol.2016 No.1
Aims: Several studies suggested that pyogenic liver abscess (PLA) was associated with colon neoplasm. Thus, colonoscopic exam for cryptogenic PLA might present the hidden colonic neoplasm, through which the intestinal flora can transmit into the liver. However, there is no prospectively enrolled cross-sectional data for colonic neoplasm in cryptogenic PLA, yet. Methods: The patients with PLA were prospectively enrolled in two university hospitals. Among them, in case of cryptogenic PLA, the all patients were recommended to perform the colonoscopic exam for detection of colonic neoplasm. Results: One hundred eighty three patients with PLA were enrolled for 22 months. Among them, 101 (55.2%) patients did not have a definite cause of liver abscess at initial evaluation. The maximal diameter of the largest lesion was 5.7 (1.0-14.0) cm, and 74.3% of the patients were treated by percutaneous abscess drainage. 91% of the patients who had an identified pathogen yielded Klebsiella. Sixty two patients had colonoscopic exam, and no one have a colonic neoplasm. Fifty patients had esophagogastroduodenoscopic exam, and 9 have a gastric ulcer and one did esophageal ulcer, and another one did hemorrhagic gastritis. Conclusions: The prevalence of colonic neoplasm among the patients with cryptogenic PLA was not as high as the previous studies. The further well-designed and large scale studies are required to confirm the association of the colon neoplasm and cryptogenic PLA.
Hepatitis E Virus: Epidemiology, Diagnosis, and Management
( Nae-yun Heo ) 대한간학회 2019 Postgraduate Courses (PG) Vol.2019 No.1
Hepatitis E virus (HEV) has been known as a cause of water-borne outbreak of acute non-A non-B hepatitis in developing countries, which affects young people and may produce high mortality in pregnant women. However, in recent decades, HEV genotypes 3 and 4 are known as a cause of sporadic zoonotic infection in older male from swine HEV worldwide. Most acute HEV infection is self-limited. But, in immunosuppressed patient including solid organ transplant recipient, chronic HEV infection may exist and progress to liver cirrhosis or decompensation. Therefore, physicians are required to recognize HEV as a major pathogen for acute and chronic hepatitis of unknown cause and investigate the test relevantly.
( Nae-yun Heo ),( Seung Ha Park ),( Joon Hyuk Choi ),( Eunju Kim ),( Jun-Seong Hwang ) 대한간학회 2020 춘·추계 학술대회 (KASL) Vol.2020 No.1
Aims: Steatohepatitis related to metabolic syndrome is a chronic liver disease which is prevalent in the patients not only with NASH but also with alcoholic liver disease, and chronic viral hepatitis. However, there is limited data dealing with the effect of hepatotonics for recovery of necro-inflammation and fibrosis in these patients. Therefore, we were intended to evaluate the efficacy of a combined hepatotonic agent in this study population. Methods: We randomly assigned 33 adults with chronic liver disease with one or more component of metabolic syndrome to receive biphenyl dimethyl dicarboxylate (12.5 mg)/ursodeoxycholic acid (50 mg), or placebo for 24 weeks. The primary outcome was a normalization of ALT (≤40 U/L). Secondary outcomes were the change of controlled attenuation parameter (CAP) and transient elastography (TE), and Chronic Liver Disease Questionnaire (CLDQ) score. Results: Thirty three patients were randomly assigned to each group. Eight (50%) of 16 patients who received intervention drug showed normalization of ALT compared with one (6%) of 17 patients in the placebo group in ITT analysis (P=0.007). In contrast, the change of CAP (-0.96 ± 1.72 dB/m vs. -0.59±1.54 dB/m; P=0.529), and TE (-10.75±26.33 kPa vs. -11.76±35.22 kPa; P=0.926), and CLDQ score ([median (IQR)] 2.50 (0.00- 11.00) vs. 9.00 (4.00-17.00), P=0.078) were not significant different between two groups. ALT was significantly changed during the four assessment periods (P<0.001), and this change was affected by group (P=0.023). The interaction between group and time was also statistically significant (P<0.001) (Fig. 1). AST was significantly changed during the four assessment periods (P<0.001). However, this change was not affected by group (P=0.544) (Fig. 2). Conclusions: Biphenyl dimethyl dicarboxylate/ursodeoxycholic acid combination reduced ALT in chronic liver disease related to metabolic syndrome. However, there is no evidence supporting that this leads to the improvement hepatic steatosis and fibrosis within 6 months.
( Nae Yun Heo ),( Young Suk Lim ),( Han Chu Lee ),( Yung Sang Lee ),( Kang Mo Kim ),( Kwan Soo Byun ),( Kwang Hyub Han ),( Kwan Sik Lee ),( Seung Woon Paik ),( Seung Kew Yoon ),( Dong Jin Suh ) 대한간학회 2013 Clinical and Molecular Hepatology(대한간학회지) Vol.19 No.1
Background/Aims: Identifying the impact of a patient`s ethnicity on treatment responses in clinical practice may assist in providing individualized treatment regimens for chronic hepatitis C (CHC). The effectiveness of standard peginterferon plus ribavirin therapy and the need for triple combination therapy with protease inhibitors in Koreans remain matters of debate. These issues were investigated in the present study. Methods: The clinical data of 272 treatment-na?ve Korean CHC patients who were treated in a community-based clinical trial (Clinical Trial group; n=51) and in clinical practice (Cohort group; n=221), were analyzed and compared. All were treated with standard protocols of peginterferon alfa-2a plus ribavirin therapy. Results: For patients with hepatitis C virus (HCV) genotype 1, the sustained virological response (SVR) rates in the Clinical Trial and Cohort groups were 81% (21/26) and 55% (58/106), respectively, by intention-to-treat (ITT) analysis ( P=0.02), and 100% (13/13) and 80% (32/40), respectively, in treatment-adherent patients ( P=0.18). For patients with HCV genotype 2, the SVR rates in these two groups were 96% (24/25) and 88% (101/115), respectively, by ITT analysis ( P=0.31). Adherence and treatment duration were independent predictors of SVR for genotypes 1 and 2, respectively ( P<0.01 for each). Korean patients with CHC achieved high SVR rates with peginterferon alfa-2a plus ribavirin in both the clinical trial and clinical practice settings. Conclusions: Measures to raise adherence to standard therapy in clinical practice may improve the SVR rates in these patients as effectively as adding protease inhibitors, thus obviating the need for the latter. (Clin Mol Hepatol 2013;19:60-69)